The English-language study highlights how economic, regulatory and sector-specific developments are influencing transaction dynamics in the healthcare and life sciences sector (HCLS) and why, compared to the previous year, more selective and strategically driven deal activity is expected in 2026. Executives are provided with a sound basis for prioritising investment decisions according to clear criteria and implementing them in a targeted manner under challenging market conditions.